No hay productos en el carrito



Monoamine Oxidase Inhibitors. Clinical Pharmacology, Benefits, and Potential Health Risks
Sharma, S.
1ª Edición Enero 2016
Inglés
Tapa dura
360 pags
1000 gr
null x null x null cm
ISBN 9781634836005
Editorial NOVA SCIENCE PUBLISHERS INC. U.S.
LIBRO IMPRESO
-5%
289,74 €275,25 €IVA incluido
278,60 €264,66 €IVA no incluido
Recíbelo en un plazo de
2 - 3 semanas
Description
This book provides basic and applied knowledge about monoamine oxidase inhibitors (MAOIs), their classification, and clinical application as neuroprotective agents and will be a valuable source of new knowledge for doctors, patients, medical students, teachers, researchers, and basic biomedical scientists interested in learning the appropriate clinical application of MAOIs without any misunderstanding for the prevention and/or treatment of neurological and neuropsychiatric disorders. The book will be of immediate interest to patients suffering from Parkinson's disease (PD), Alzheimer's disease (AD), post-traumatic stress disorders (PTSD), panic disorders, attention deficit hyperactivity disorders (ADHD), and major depression. Physicians interested in learning more about MAOIs and their molecular and pharmacological mechanism of action will highly benefit from the book's clinically-interesting contents. In general, this book will be a valuable source of knowledge for the basic researcher, clinically useful for the physician, and therapeutically-beneficial for the patients. The book can also serve as a guide for Masters and Ph.D students interested in conducting research on MAOIs. Particularly, MD doctors, students, and professors will find this book interesting to enhance their basic knowledge about MAOIs and their potential benefits and adverse effects for the better clinical management of drug-resistant PD, AD, and MDDs. Furthermore, recent knowledge regarding the molecular mechanism of MAOIs-mediated protection at the cellular, molecular, and genetic level is thought-provoking and motivates the young scientists to augment research on developing novel drugs with minimum or no adverse effects. It is envisaged that future research on specific CB-targeted MAOIs will have superior pharmacogenomics profiles, enhanced margin of safety, maximum therapeutic index, and minimum or no adverse effects.'
Table of contents
Preface
Acknowledgement
pp. xxxvii
About the Author
pp. xxxix-xl
About this Book
pp. xli-xlvi
Words of Wisdom
pp. xlvii-xlviii
Abbreviations
pp. xlix-lii
Chapter 1
MAOIs (Historical Perspectives and Earlier Studies)
pp. 1-32
Chapter 2
Synthetic and Herbal MAOIs
pp. 33-78
Chapter 3
Molecular Pharmacology of Monoamine Oxidase Inhibitors
pp. 79-116
Chapter 4
Specific Monoamine-Oxidase-A inhibitors (Moclobemide, Safinamide, & Labazemide)
pp. 117-128
Chapter 5
Specific MAO-B Inhibitors (Therapeutic Role of Selegiline and Rasagiline)
pp. 129-176
Chapter 6
Therapeutic Potential of MAOIs (Recent Update-1)
pp. 177-206
Chapter 7
Therapeutic Potential of MAOIs (Recent Update-2)
pp. 207-222
Chapter 8
Therapeutic Potential of MAOIs (Recent Update-3)
pp. 223-236
Chapter 9
Therapeutic Potential of MAOIs (Recent Update-4)
pp. 237-270
Chapter 10
Therapeutic Potential of MAOIs (Recent Update-5)
pp. 271-310
Chapter 11
Therapeutic Potential of MAOIs (Recent Update-6)
pp. 311-320
Chapter 12
Dietary and Drug Restrictions With MAOIs
pp. 321-344
Chapter 13
Adverse Reactions with MAOIs (Recent Update)
pp. 345-384
Index
© 2025 Axón Librería S.L.
2.149.0